Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mikrochim Acta ; 191(1): 53, 2023 12 27.
Artigo em Inglês | MEDLINE | ID: mdl-38151630

RESUMO

A fluorescence antibody microarray has been developed for the determination of relevant cardiovascular disease biomarkers for the analysis of human plasma samples. Recording characteristic protein molecular fingerprints to assess individual's states of health could allow diagnosis to go beyond the simple identification of the disease, providing information on its stage or prognosis. Precisely, cardiovascular diseases (CVDs) are complex disorders which involve different degenerative processes encompassing a collection of biomarkers related to disease progression or stage. The novel approach that we propose is a fluorescent microarray chip has been developed accomplishing simultaneous determination of the most significant cardiac biomarkers in plasma aiming to determine the CVD status stage of the patient. As proof of concept, we have chosen five relevant biomarkers, C-reactive protein (CRP) as biomarker of inflammation, cystatin C (CysC) as biomarker of renal failure that is directly related with heart failure, cardiac troponin I (cTnI) as already established biomarker for cardiac damage, heart fatty acid binding protein as biomarker of ischemia (H-FABP), and finally, NT-proBNP (N-terminal pro-brain natriuretic peptide), a well-established heart failure biomarker. After the optimization of the multiplexed microarray, the assay allowed the simultaneous determination of 5 biomarkers in a buffer solution reaching LODs of 15 ± 5, 3 ± 1, 24 ± 3, 25 ± 3, and 3 ± 1 ng mL-1, for CRP, CysC, H-FABP, cTnI, and NT-proBNP, respectively. After solving the matrix effect, and demonstrating the accuracy for each biomarker, the chip was able to determine 24 samples per microarray chip. Then, the microarray has been used on a small pilot clinical study with 29 plasma samples from clinical patients which suffered different CVD and other related disorders. Results show the superior capability of the chip to provide clinical information related to the disease in terms of turnaround time (1 h 30 min total assay and measurement) and amount of information delivered in respect to reference technologies used in hospital laboratories (clinical analyzers). Despite the failure to detect c-TnI at the reported threshold, the microarray technology could be a powerful approach to diagnose the cardiovascular disease at early stage, monitor its progress, and eventually providing information about an eminent potential risk of suffering a myocardial infarction. The microarray chip here reported could be the starting point for achieving powerful multiplexed diagnostic technologies for the diagnosis of CVDs or any other pathology for which biomarkers have been identified at different stages of the disease.


Assuntos
Doenças Cardiovasculares , Insuficiência Cardíaca , Humanos , Doenças Cardiovasculares/diagnóstico , Proteína 3 Ligante de Ácido Graxo , Biomarcadores , Prognóstico , Proteína C-Reativa/análise
2.
ACS Infect Dis ; 8(3): 645-656, 2022 03 11.
Artigo em Inglês | MEDLINE | ID: mdl-35175740

RESUMO

An immunochemical strategy to detect and quantify AIP-IV, the quorum sensing (QS) signaling molecule produced by Staphylococcus aureusagr type IV, is reported here for the first time. Theoretical calculations and molecular modeling studies have assisted on the design and synthesis of a suitable peptide hapten (AIPIVS), allowing to obtain high avidity and specific antibodies toward this peptide despite its low molecular weight. The ELISA developed achieves an IC50 value of 2.80 ± 0.17 and an LOD of 0.19 ± 0.06 nM in complex media such as 1/2 Tryptic Soy Broth. Recognition of other S. aureus AIPs (I-III) is negligible (cross-reactivity below 0.001%), regardless of the structural similarities. A pilot study with a set of clinical isolates from patients with airways infection or colonization demonstrates the potential of this ELISA to perform biomedical investigations related to the role of QS in pathogenesis and the association between dysfunctional agr or the agr type with unfavorable clinical outcomes. The AIP-IV levels could be quantified in the low nanomolar range in less than 1 h after inoculating agr IV-genotyped isolates in the culture broth, while those genotyped as I-III did not show any immunoreactivity after a 48 h growth, pointing to the possibility to use this technology for phenotyping S. aureus. The research strategy here reported can be extended to the rest of the AIP types of S. aureus, allowing the development of powerful multiplexed chips or point-of-care (PoC) diagnostic devices to unequivocally identify its presence and its agr type on samples from infected patients.


Assuntos
Infecções Estafilocócicas , Staphylococcus aureus , Proteínas de Bactérias/química , Humanos , Peptídeos/química , Projetos Piloto , Infecções Estafilocócicas/diagnóstico
3.
ACS Nano ; 4(3): 1473-80, 2010 Mar 23.
Artigo em Inglês | MEDLINE | ID: mdl-20146439

RESUMO

A proof of concept of the electronic detection of two anabolic steroids, stanozolol (Stz) and methylboldenone (MB), was carried out using two specific antibodies and arrays of carbon nanotube field-effect transistors (CNTFETs). Antibodies specific for Stz and MB were prepared and immobilized on the carbon nanotubes (CNTs) using two different approaches: direct noncovalent bonding of antibodies to the devices and bonding the antibodies covalently to a polymer previously attached to the CNTFETs. The results indicated that CNTFETs bonded to specific antibodies covalently or noncovalently are able to detect the presence of steroids. Statistically significant changes in the threshold voltage and drain current were registered in the transistors, allowing the steroids to be recognized. On the other hand, it was determined that the specific antibodies do not detect other steroids other than Stz and MB, such as nandrolone (ND) because, in this case, statistically significant changes in the transistors were not detected. The polymer prevents the aggregation of antibodies on the electrodes and decreases the transistor hysteresis. Nevertheless, it is not able to avoid the nonspecific adsorption of streptavidin, meaning that nonspecific adsorption on CNTs remains a problem and that this methodology is only useful for purified samples. Regarding the detection mechanism, in addition to charge transfer, Schottky barrier, SB, modification, and scattering potential reported by other authors, an electron/hole trapping mechanism leading to hysteresis modification has been determined. The presence of polymer seems to hinder the modulation of the electrode-CNT contact.


Assuntos
Anabolizantes/análise , Técnicas Biossensoriais/métodos , Elétrons , Imunoensaio/métodos , Nanotubos de Carbono/química , Esteroides/análise , Transistores Eletrônicos , Adsorção , Anabolizantes/imunologia , Animais , Anticorpos Imobilizados/química , Anticorpos Imobilizados/imunologia , Especificidade de Anticorpos , Técnicas Biossensoriais/instrumentação , Eletrodos , Imunoensaio/instrumentação , Estanozolol/análise , Estanozolol/imunologia , Esteroides/imunologia , Estreptavidina/análise , Estreptavidina/química , Estreptavidina/imunologia , Especificidade por Substrato , Testosterona/análogos & derivados , Testosterona/análise , Testosterona/química , Testosterona/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...